Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

2017

Hematological Oncology, 35, 4, (2017), pp. 497-503

Article / Letter to editor

Please use this identifier to cite or link to this item: https://hdl.handle.net/2066/181295

Display more details

Upload full text

Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.

Radboud Repository